Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
08 07 2019
Historique:
received: 20 12 2018
accepted: 13 06 2019
entrez: 10 7 2019
pubmed: 10 7 2019
medline: 17 7 2020
Statut: epublish

Résumé

Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer's disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk. Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures. Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups. Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic.

Sections du résumé

BACKGROUND
Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer's disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk.
METHODS
Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures.
RESULTS
Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups.
CONCLUSIONS
Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic.

Identifiants

pubmed: 31286994
doi: 10.1186/s13195-019-0514-z
pii: 10.1186/s13195-019-0514-z
pmc: PMC6615169
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT01638949']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61

Subventions

Organisme : Fondation Plan Alzheimer
ID : Alzheimer Plan 2008-2012
Pays : International
Organisme : Programme Hospitalier de Recherche Clinique (FR)
ID : PHRCN 2011-A01493-38 and PHRCN 2012 12-006-0347
Pays : International
Organisme : Agence Nationale de la Recherche
ID : LONGVIE 2007
Pays : International
Organisme : Association France Alzheimer et maladies apparentées (FR)
ID : AAP 2013
Pays : International

Références

Cereb Cortex. 2019 May 1;29(5):1889-1899
pubmed: 29668866
Alzheimers Dement. 2019 Mar;15(3):465-476
pubmed: 30555032
Arch Neurol. 2012 Feb;69(2):223-9
pubmed: 22332189
Biol Psychiatry. 2008 Mar 15;63(6):609-18
pubmed: 17720148
J Neurosci. 2008 Jun 11;28(24):6174-81
pubmed: 18550759
Neurobiol Aging. 2006 Dec;27(12):1751-6
pubmed: 16309795
Neurology. 2008 Oct 7;71(15):1152-9
pubmed: 18838662
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S99-S107
pubmed: 26402087
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S109-14
pubmed: 26402081
Am J Geriatr Psychiatry. 2015 Sep;23(9):985-93
pubmed: 25746485
Sci Rep. 2017 Aug 31;7(1):10160
pubmed: 28860449
Int J Geriatr Psychiatry. 2012 Apr;27(4):394-400
pubmed: 21560161
Neurology. 2012 Sep 25;79(13):1332-9
pubmed: 22914828
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Psychol Med. 2004 Nov;34(8):1495-506
pubmed: 15724880
Brain. 2010 Apr;133(Pt 4):1163-72
pubmed: 20375138
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neurol. 2004 Jun;251(6):671-5
pubmed: 15311341
Neuropsychologia. 2012 Oct;50(12):2880-6
pubmed: 22940426
Dement Geriatr Cogn Disord. 2010;29(1):75-81
pubmed: 20110703
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S141-50
pubmed: 26402076
Neurobiol Aging. 2003 Jan-Feb;24(1):95-103
pubmed: 12493555
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
BMC Psychiatry. 2011 Jul 01;11:108
pubmed: 21722382
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
J Neuropsychiatry Clin Neurosci. 2009 Spring;21(2):199-205
pubmed: 19622691
Brain. 2008 Jan;131(Pt 1):60-71
pubmed: 18063588
Alzheimers Dement. 2017 Jul;13(7):783-791
pubmed: 28034600
Am J Geriatr Psychiatry. 2011 Apr;19(4):327-34
pubmed: 21427641
Int J Geriatr Psychiatry. 2001 Feb;16(2):168-74
pubmed: 11241722
Brain Connect. 2013;3(4):353-62
pubmed: 23627661
Alzheimers Dement. 2014 May;10(3):319-27
pubmed: 23871264
Neurology. 2015 Jul 7;85(1):56-62
pubmed: 26048028
J Anxiety Disord. 2013 Aug;27(6):567-75
pubmed: 23298889
Alzheimers Dement (Amst). 2016 Dec 18;5:23-34
pubmed: 28054025
Neurocase. 2005 Feb;11(1):14-25
pubmed: 15804920
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
Alzheimers Dement (Amst). 2015 May 02;1(2):194-205
pubmed: 27239504
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
J Alzheimers Dis. 2015;49(4):1115-22
pubmed: 26639956
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):11-6
pubmed: 22001316
Ageing Res Rev. 2016 Sep;30:25-48
pubmed: 26827786
Neurology. 2006 Sep 12;67(5):834-42
pubmed: 16966547
Alzheimers Dement. 2010 Jan;6(1):11-24
pubmed: 20129317
Int J Aging Hum Dev. 1997;45(3):207-21
pubmed: 9438876
Dement Geriatr Cogn Disord. 2007;24(3):213-9
pubmed: 17690554
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Alzheimers Dement. 2015 Jun;11(6):e1-120
pubmed: 26073027
Rev Neurosci. 2010;21(3):187-221
pubmed: 20879692
Alzheimers Dement. 2014 Jan;10(1):99-108
pubmed: 23867795
Arch Gerontol Geriatr. 2013 Jul-Aug;57(1):110-5
pubmed: 23462582
J Am Geriatr Soc. 2004 Dec;52(12):2045-51
pubmed: 15571540
Brain Imaging Behav. 2019 Apr;13(2):554-563
pubmed: 29744801
Neurology. 2012 Oct 9;79(15):1570-7
pubmed: 22972644
JAMA Psychiatry. 2016 May 1;73(5):525-31
pubmed: 26982217
Sleep Sci. 2015 Jan-Mar;8(1):36-41
pubmed: 26483941
J Affect Disord. 2002 Nov;72(2):157-65
pubmed: 12200206
Neurology. 2008 Apr 29;70(18):1601-7
pubmed: 18443310
J Neurosci. 2012 Nov 14;32(46):16265-73
pubmed: 23152610
Neurology. 2015 Nov 24;85(21):1852-8
pubmed: 26511452
Front Psychiatry. 2014 Apr 23;5:40
pubmed: 24795656
Alzheimers Dement. 2015 Nov;11(11):1385-92
pubmed: 25667997
Acta Neurol Scand. 2013 May;127(5):344-50
pubmed: 23215819
Neurobiol Aging. 2009 Jan;30(1):112-24
pubmed: 17630048
Alzheimers Dement. 2014 Jan;10(1):93-8
pubmed: 23562429
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9
pubmed: 26402082
Am J Psychiatry. 1982 Sep;139(9):1136-9
pubmed: 7114305
J Gerontol A Biol Sci Med Sci. 2016 Sep;71(9):1210-5
pubmed: 26946100
Int J Geriatr Psychiatry. 2009 Feb;24(2):190-6
pubmed: 18642390
Gerontologist. 2013 Jun;53(3):462-73
pubmed: 22961464
Alzheimers Dement (Amst). 2015 Mar 1;1(1):33-40
pubmed: 25938132
Annu Rev Clin Psychol. 2017 May 8;13:369-396
pubmed: 28482688
J Alzheimers Dis. 2015;43(2):677-86
pubmed: 25114076
Int Psychogeriatr. 2013 Aug;25(8):1307-15
pubmed: 23693133
Alzheimers Dement. 2014 Jan;10(1):76-83
pubmed: 23375567
JAMA Psychiatry. 2015 Mar;72(3):284-91
pubmed: 25629787
J Gerontol B Psychol Sci Soc Sci. 2019 Jan 10;74(2):202-211
pubmed: 28633326
JAMA Neurol. 2015 Apr;72(4):446-54
pubmed: 25706191
Aging Ment Health. 2017 May;21(5):532-536
pubmed: 26689628
J Neurosci. 2015 Jul 22;35(29):10402-11
pubmed: 26203136
Br Med Bull. 2014 Dec;112(1):71-81
pubmed: 25274571
Alzheimers Dement. 2010 May;6(3):239-46
pubmed: 20451872
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
J Alzheimers Dis. 2010;19(1):137-45
pubmed: 20061633
J Alzheimers Dis. 2015;46(1):63-73
pubmed: 25697700
Sleep. 2013 Sep 01;36(9):1327-34
pubmed: 23997365
Brain. 2017 Dec 1;140(12):3317-3328
pubmed: 29194503
Arch Gen Psychiatry. 2010 Apr;67(4):414-22
pubmed: 20368517

Auteurs

Elizabeth Kuhn (E)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Inès Moulinet (I)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Audrey Perrotin (A)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Renaud La Joie (R)

Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Brigitte Landeau (B)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Clémence Tomadesso (C)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.
Normandie Univ, UNICAEN, PSL Recherche Universités, EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, GIP Cyceron, 14000, Caen, France.

Alexandre Bejanin (A)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Siya Sherif (S)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Vincent De La Sayette (V)

Normandie Univ, UNICAEN, PSL Recherche Universités, EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, GIP Cyceron, 14000, Caen, France.
CHU de Caen, Service de Neurologie, Caen, France.

Béatrice Desgranges (B)

Normandie Univ, UNICAEN, PSL Recherche Universités, EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, GIP Cyceron, 14000, Caen, France.

Denis Vivien (D)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.
Department of Clinical Research, Caen Normandy Hospital (CHU) de Caen, 14000, Caen, France.

Géraldine Poisnel (G)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France.

Gaëlle Chételat (G)

Inserm, Inserm UMR-S U1237, GIP Cyceron, Université de Caen-Normandie, Boulevard H. Becquerel, 14000, Caen, France. chetelat@cyceron.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH